Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies

Oral Oncology

Volumn 42, Issue 8, 2006, Pages 759-769

  Dodd, R L ^a   Slevin, N J ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adenoid cystic carcinoma; Biological therapies; Chemotherapy; Review; Salivary

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CISPLATIN; CYCLINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; IMATINIB; KI 67 ANTIGEN; LAPATINIB; METHOTREXATE; NILOTINIB; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN BCL 2; PROTEIN P53; STEM CELL FACTOR; TRANSCRIPTION FACTOR SOX4; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOID CYSTIC; HUMANS; NEOPLASM PROTEINS; SALIVARY GLAND NEOPLASMS; TREATMENT OUTCOME;

EID: 33748120900     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.01.001     Document Type: Review

References (122)

1. Khan A.J., DiGiovanna M.P., Ross D.A., Sasaki C.T., Carter D., Son Y.H., et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96 3 (2001) 149-158
2. Chummun S., McLean N.R., Kelly C.G., Dawes P.J.D.K., Meikle D., Fellows S., et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg 54 6 (2001) 476-480
3. Wiseman S.M., Popat S.R., Rigual N.R., Hicks W.L., Orner J.B., Wein R.O., et al. Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J 81 8 (2002) 510-518
4. van der Wal J.E., Becking A.G., Snow G.B., and van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 24 8 (2002) 779-783
5. Spiro R.H., Huvos A.G., and Strong E.W. Adenoid cystic carcinoma: factors influencing survival. Am J Surg 138 4 (1979) 579-583
6. Bradley P.J. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg 12 (2004) 127-132
7. Hotte S.J., Winquist E.W., Lamont E., MacKenzie M., Vokes E., Chen E.X., et al. Imatinib mesylate in patients with adenoid cystic carcinoma of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J Clin Oncol 23 3 (2005) 585-590
8. Jones A.S., Hamilton J.W., Rowley H., Husband D., and Helliwell T.R. Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol 22 5 (1997) 434-443
9. Spiro R.H. Distant metastases in adenoid cystic carcinoma of salivary origin. Am J Surg 174 5 (1997) 495-498
10. Eby L.S., Johnson D.S., and Baker H.W. Adenoid cystic carcinoma of the head and neck. Cancer 29 (1972) 1160-1168
11. Fordice J., Kershaw C., El-Naggar A., and Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125 2 (1999) 149-152
12. Hashimoto S., Takahashi H., Okamoto M., Yao K., Nakayama M., Makoshi T., et al. Prognostic factors of head and neck adenoid cystic carcinoma: quantitative morphological analysis of 19 cases. Acta Otolaryngol 547 S (2002) 93-96
13. Perzin K.H., Gullane P., and Clairmont A.C. Adenoid cystic carcinoma arising in salivary glands. Cancer 42 (1978) 265-282
14. Spiro R.H., and Huvos A.G. Stage means more than grade in adenoid cystic carcinoma. Am J Surg 164 6 (1992) 623-628
15. Batsakis J.G., Luna M.A., and El-Naggar A. Histopathological grading of salivary gland neoplasms: III. Adenoid cystic carcinomas. Ann Otol Rhinol Laryngol 99 (1990) 1007-1009
16. Garden A.S., Weber R.S., Morrison W.H., Kian Ang K.K., and Peters L.J. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 32 3 (1995) 619-626
17. Spiro R.H., Huvos A.G., and Strong E.W. Adenoid cystic carcinoma of salivary origin: a clinicopathologic study of 242 cases. Am J Surg 128 (1974) 512-520
18. Dal Maso M., and Lippi L. Adenoid cystic carcinoma of the head and neck: a clinical study of 37 cases. Laryngoscope 95 2 (1985) 177-181
19. Wahlberg P., et al. Carcinoma of the parotid and submandibular glands-a study of survival in 2565 patients. Oral Oncol 38 7 (2002) 706-713
20. http://www.orgsites.com/ca/acco/.
21. Licitra L., Marchini S., Spinazzè S., Rossi A., Rocca A., Grandi C., et al. Cisplatin in advanced salivary gland carcinoma: a phase II study of 25 patients. Cancer 68 (1991) 1874-1877
22. Schramm V.L., Srodes C., and Myers E.N. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 107 (1981) 739-741
23. Kaplan M.J., Johns M.E., and Cantrell R.W. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 95 (1986) 165-170
24. Suen J.Y., and Johns M.E. Chemotherapy for salivary gland cancer. Laryngoscope 92 (1982) 235-239
25. de Haan L.D., De Mulder P.H.M., Vermorken J.B., Schnornagel J.H., Vermey A., and Verweij J. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 14 (1992) 273-277
26. Vermorken J.B., Verweij J., de Mulder P.H.M., Cognetti F., Clavel M., Rodenhuis S., et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative group. Ann Oncol 4 (1993) 785-788
27. Verweij J., de Mulder P.H.M., de Graeff A., Vermorken J.B., Wildiers J., Kerger J., et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. Ann Oncol 7 (1996) 867-869
28. Tannock I.F., and Sutherland D.J. Chemotherapy for adenocystic carcinoma. Cancer 46 (1980) 452-454
29. Airoldi M., Pedani F., Succo G., Gabriele A.M., Ragona R., Marchionatti S., et al. Phase II randomised trial comparing Vinorelbine versus Vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91 (2001) 541-547
30. Airoldi M., Bumma C., Bertetto O., Gabriele P., Succo G., and Pedani F. Vinorelbine treatment of recurrent salivary gland carcinomas. Bull Cancer 85 (1998) 892-894
31. Spiers A.S.D., Esseltine D.L.W., Ruckdeschel J.C., Davies J.N.P., and Horton J. Metastatic adenoid cystic carcinoma of salivary glands: case reports and review of literature. Cancer Control 3 4 (1996) 336-342
32. Hill M.E., Constenla D.O., A'Hern R.P., Henk J.M., Rhys-Evans P., Breach N., et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33 4 (1997) 275-278
33. Jones A.S., Phillips D.E., Cook J.A., and Helliwell T.R. A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer 67 (1993) 112-114
34. Venook A.P., Tseng A., Frederick J.M., Silverberg I., Boles R., Fu K.K., et al. Cisplatin, doxorubicin and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 5 (1987) 951-955
35. Airoldi M., Pedani F., Brando V., Gabriele P., and Giordano C. Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 75 (1989) 252-256
36. Airoldi M., Fornani G., Pedani F., Marchionatti S., Gabriele P., Succo G., et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 20 (2000) 3781-3784
37. Posner M.R., Ervin T.J., Weichselbaum R.R., Fabian R.L., and Miller D. Chemotherapy of advanced salivary gland neoplasms. Cancer 50 (1982) 2261-2264
38. Belani C.P., Eisenberger M.A., and Gray W.C. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediat Oncol 16 (1988) 197-202
39. Dreyfuss A.I., Clark J.R., Fallon B.G., Posner M.R., Norris C.M., and Miller D. Cyclophosphamide, doxorubicin and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 60 (1987) 2869-2872
40. Tsukuda M., Kokatsu T., Ito K., Mochimatsu I., Kubota A., and Sawaki S. Chemotherapy for recurrent adeno- and adenoid cystic carcinomas in the head and neck. J Cancer Res Clin Oncol 119 (1993) 756-758
41. Licitra L., Cavina R., Grandi C., DiPalma S., Guzzo M., Demicheli R., et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: a phase II trial of 22 patients. Ann Oncol 7 6 (1996) 640-642
42. Dimery I.W., Legha S.S., Shirinian M., and Ki Hong W. Fluorouracil, doxorubicin, cyclophosphamide and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 8 6 (1990) 1056-1062
43. Airoldi M., Brando V., Giordano C., Gabriele P., Bussi M., and Cortesina G. Chemotherapy for recurrent salivary gland malignancies: experience of the ENT department of Turin University. ORL 56 (1994) 105-111
44. Triozzi P.L., Brantley A., Fisher S., Boyce Cole T., Crocker I., and Huang A.T. 5-Fluorouracil, cyclophosphamide and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 59 (1987) 887-890
45. Forastiere A.A., Baker S.R., Wheeler R., and Medvec B.R. Intra-arterial cisplatin and 5-fluorodeoxyuridine in advanced malignancies confined to the head and neck. J Clin Oncol 5 (1987) 1601-1606
46. Samson D.J., Seidenfeld J., Ziegler K., and Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22 17 (2004) 3618-3630
47. Boven E., Winograd B., Berger D.P., Dumont M.P., Braakhuis B.J., Fodstad O., et al. Phase II preclinical drug screening in human tumour xenografts: a first European multicentre collaborative study. Cancer Res 52 21 (1992) 5940-5947
48. Berger D.P., Henss H., Winterhalter B.R., and Fiebig H.H. The clonogenic assay with human tumour xenografts: evaluation, predictive value and application for drug screening. Ann Oncol 1 5 (1990) 333-341
49. Bosanquet A.G., and Bell P.B. Ex vivo therapeutic index by drug sensitivity assay using human normal and tumour cells. J Exp Ther Oncol 4 2 (2004) 145-154
50. Mason J.M., Drummond M.F., Bosanquet A.G., and Sheldon T.A. The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukaemia. Int J Technol Assess Health Care 15 1 (1999) 173-184
51. Went P.T., Dirnhofer S., Bundi M., Mirlacher M., Schraml P., Mangialaio S., et al. Prevalence of KIT expression in human tumours. J Clin Oncol 22 22 (2004) 4514-4522
52. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 21 23 (2003) 4342-4349
53. Zhang P., Gao W.Y., Turner S., and Ducatman B.S. Glivec inhibits lung cancer cell growth and potentiates the cisplatin effect in vitro. Mol Cancer 2 (2003) 1
54. Jeng Y.M., Lin C.Y., and Hsu H.C. Expression of the c-kit protein is associated with certain sub-types of salivary gland carcinoma. Cancer Lett 154 (2000) 107-111
55. Edwards P.C., Bhuiya T., and Kelsch R.D. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 5 (2003) 586-593
56. Holst V.A., Marshall C.E., Mosaluk C.A., and Frierson H.F. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12 10 (1999) 956-960
57. Penner C.R., Folpe A.L., and Budnick S.D. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 15 7 (2002) 687-691
58. Chandan V.S., Wibur D., Faquin W.C., and Khurana K.K. Is c-kit immunolocalisation in cell block preparations useful in the differentiation of adenoid cystic carcinoma from pleomorphic adenoma?. Cancer 102 4 (2004) 207-209
59. Pfeffer R, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. Imatinib for advanced adenoid cystic carcinoma of the head and neck. A phase II study. American Association of Cancer Research abstract 2005.
60. Alcedo J.C., Fábrega J.M., Arosemena J.R., and Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 26 (2004) 829-831
61. http://www.nrr.nhs.uk/search.htm.
62. www.clinicaltrials.gov.
63. Mastropasqua M.G., Maiorano E., Pruneri G., Orvieto E., Mazzarol G., Vento A.R., et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol 18 10 (2005) 1277-1282
64. Slevin N.J., Mais K.L., Bruce I., Ward T., Carrington B., Hulse P., et al. Imatinib with cisplatin in recurrent and/or metastatic salivary adenoid cystic carcinoma-response assessed by FDG-PET scanning. J Clin Oncol 22 14S (2004) 5604 [abstract]
65. http://www.cancerwise.org/may_2005/display.cfm?id=95DFD685-67CE-4F48-87672680A929EB95&method=displayFull&color=red.
66. http://www.foxnews.com/story/0,2933,140552,00.html.
67. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82 2-3 (1999) 241-250
68. Scholl S., Beuzeboc P., and Pouillart P. Targeting HER2 in other tumour types. Ann Oncol 12 S1 (2001) 81-87
69. Dori S., Vered M., David R., and Buchner A. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 31 8 (2002) 463-467
70. Kusafuka K. Expressions of oncogene products in adenoid cystic carcinomas of salivary glands: immunohistochemical study. Kobubyo Gakkai Zasshi 58 4 (1991) 696-717
71. Gibbons M.D., Manne U., Carroll W.R., Peters G.E., Weiss H.L., and Grizzle W.E. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111 8 (2001) 1373-1378
72. Shintani S., Funayama T., Yoshihama Y., Alcalde R.E., Ootsuki K., Terakado N., et al. Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res 15 (1995) 2623-2626
73. Chen C.H., Li B.Y., Wan J.T., Sun A., Leu J.S., and Chiang C.P. Expression of epidermal growth factor in salivary gland adenoid cystic carcinoma. Proc Natl Sci Counc Repub China B 25 2 (2001) 90-96
74. Vered M., Braunstein E., and Buchner A. Immmunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24 (2002) 632-636
75. Chiang C.P., Chen C.H., Liu B.Y., Sun A., Leu J.S., and Wang J.T. Expression of transforming growth factor-alpha in adenoid cystic carcinoma of the salivary gland. J Formos Med Assoc 100 7 (2001) 471-477
76. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer. In: 2005 ASCO annual meeting [abstract].
77. Baslega J., and Averbuch S.D. ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 Suppl. 1 (2000) 33-40
78. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 Suppl. 1 (2000) 25-32
79. http://www.cancer.gov/clinicaltrials.
80. Glisson B., Colevas A.D., Haddad R., Krane J., El-Naggar A., Kies M., et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10 (2004) 944-946
81. Cho K.J., Lee S.S., and Lee Y.S. Proliferating cell nuclear antigen and C-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck 21 (1999) 414-419
82. Karja V., Syrjanen S., Kataja V., and Syrjanen K. C-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec 56 4 (1994) 206-212
83. Kerhonan N.M., Blessing K., King G., Corbett I.P., and Miller I.D. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol 163 1 (1991) 77-80
84. Sugano S., Mukai K., Tsuda H., Hirohashi S., Furuya S., Shimosato Y., et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102 8 (1992) 923-927
85. Shrestha P., Huang J.W., Tsuji T., Shinozaki F., Maeda K., Sasaki K., et al. Rare expression of the c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Oral Pathol Med 21 (1992) 477-480
86. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
87. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
88. Haddad R., Dimitrios Colevas A., Krane J.F., Cooper D., Glisson B., Amrein P.C., et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 39 (2003) 724-727
89. Dimery I.W., Jones L.A., Verjan R.P., Raymond A.K., Goepfert H., and Hong W.K. Estrogen receptors in normal salivary gland and salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 113 (1987) 1082-1085
90. Dori S., Trougouboff P., David R., and Buchner A. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol 36 (2000) 450-453
91. Miller A.S., Hartman G.G., Chen S.Y., Edmonds P.R., Brightman S.A., and Harwick R.D. Estrogen receptor assay in polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma of salivary gland origin. An immunohistochemical study. Oral Surg Oral Med Oral Pathol 77 1 (1994) 36-40
92. Shick P.C., Riordan G.P., and Foss R.D. Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80 4 (1995) 440-444
93. Gaffney E.V., Pinkston J.A., and Eidson J.J. Estrogen receptors in parotid tumors. Endocr Res 21 (1995) 635-643
94. Pires F.R., Perez D.E., Almeida O.P., and Kowalski L.P. Estrogen receptor expression in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma. Pathol Oncol Res 10 3 (2004) 166-168
95. Jeannon J.P., Soames J.V., Bell H., and Wilson J.A. Immunohistochemical detection of oestrogen and progesterone receptors in human salivary gland tumours. Clin Otolaryngol 24 1 (1999) 52-54
96. Ozono S., Onozuka M., Sato K., and Ito Y. Immunohistochemical localization of estradiol, progesterone, and progesterone receptor in human salivary glands and salivary adenoid cystic carcinomas. Cell Struct Funct 17 (1992) 169-175
97. Shadaba A., Gaze M.N., and Grant H.R. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 111 12 (1997) 1186-1189
98. Jia L., Esguerra R.L., Tang X., Yin H., Sakamoto K., Okada N., et al. Prognostic value of apoptosis and apoptosis-associated proteins in salivary gland adenoid cystic carcinoma. Pathol Int 54 (2004) 217-223
99. Harris C.C., and Hollstein M. Medical progress: clinical implications of the p53 tumour suppressor gene. N Engl J Med 329 18 (1993) 1318-1327
100. Alves F.A., Pires F.R., de Almeida O.P., Lopes M.A., and Kowalski L.P. PCNA, Ki-67 and p53 expression in submandibular salivary gland tumours. Int J Oral Maxillofac Surg 33 (2004) 593-597
101. Papadaki H., Finkelstein S.D., Kounelis S., Bakker A., Swalsky P.A., and Kapadia S.B. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum Pathol 27 (1996) 567-572
102. Lazzaro B., and Cleveland D. p53 and Ki-67 antigen expression in small oral biopsy specimens of salivary gland tumours. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89 5 (2000) 613-617
103. Doi R., Kuratate I., Okamoto E., Ryoke K., and Ito H. Expression of p53 oncoprotein increases intratumoural microvessel formation in human salivary gland carcinomas. J Oral Pathol Med 28 (1999) 259-263
104. Gallo O., Franchi A., Bianchi S., Boddi V., Giannelli E., and Alajmo E. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75 (1995) 2037-2044
105. Carlinfante G., Lazzaretti M., Ferrari S., Bianchi B., and Crafa P. p53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract 200 (2005) 791-799
106. Kiyoshima T., Shima K., Kobayashi I., Matsuo K., Okamura K., Komatsu S., et al. Expression of p53 tumour suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol 37 (2001) 315-322
107. Yamamoto Y., Wistuba I.I., Kishimoto Y., Virmani A.K., Vuitch F., Albores-Saavedra J., et al. Loss of heterozygosity and microsatellite alterations in p53 and RB genes in adenoid cystic carcinoma of the salivary glands. Pathol Int 48 4 (1998) 273-280
108. Zhu Q.R., White F.H., and Tipoe G.L. P53 oncoprotein accumulation in adenoid cystic carcinoma of parotid and palatine salivary glands. Pathology 229 (1997) 154-158
109. Soini Y., Kamel D., Nuorva K., Lane D.P., Vahakangas K., and Paakko P. Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virchows Arch A Pathol Anat Histopathol 421 5 (1992) 415-420
110. Karja V.J., Syrjanen K.J., Kurvinen A.K., and Syrjanen S.M. Expressions and mutations of p53 in salivary gland tumours. J Oral Pathol Med 26 5 (1997) 217-223
111. Preisegger K.H., Berham A., Kopp S., Jessernigg G., Gugl A., and Stammberger H. Prognostic impact of molecular analyses in adenoid cystic carcinoma of the salivary glands. Onkologie 24 3 (2001) 273-277
112. Chau Y., Hongyo T., Aozasa K., and Chan J.K.C. Dedifferentiation of adenoid cystic carcinoma: a report of a case implicating p53 gene mutation. Hum Pathol 32 (2001) 1403-1407
113. http://www.cancerwise.org/August_2004/.
114. Nordgård S., Franzén G., Boysen M., and Halvorsen T.B. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope 107 (1997) 531-536
115. Kim K.H., Chung P.S., Rhee C.S., and Kim W.H. The manifestation of proliferating cell nuclear antigen in adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 120 (1994) 1221-1225
116. Norberg-Spaak L., Dardick I., and Ledin T. Adenoid cystic carcinoma: use of cell proliferation, bcl-2 expression, histological grade and clinical stage as predictors of clinical outcome. Head Neck 22 (2000) 489-497
117. Murakami M., Ohtani I., Hojo H., and Wakasa H. Immunohistochemical evaluation with Ki-67: an application to salivary gland tumours. J Laryngol Otol 196 (1992) 35-38
118. Yanez M., Roa I., Garcia M., Ibacache G., and Villaseca M. Bcl-2 gene protein expression in salivary gland tumours. Rev Med Chil 127 2 (1999) 139-142
119. Frierson H.F., El-Naggar A.K., Welsh J.B., Sapinoso L.M., Su A.I., Cheng J., et al. Large scale molecular analysis identifies genes with altered expression in salivary gland adenoid cystic carcinoma. Am J Pathol 161 4 (2002) 1315-1323
120. El-Rifai W., Rutherford S., Knuutila S., Frierson H.F., and Moskaluk C.A. Novel DNA copy number losses in chromosome 12q12-q13 in adenoid cystic carcinoma. Neoplasia 3 3 (2001) 173-178
121. Enamorado I., Lakhani R., Korkmaz H., Yoo G.H., Del Mar Alonso M., Pietraszkiewicz H., et al. Correlation of histopathological variants, cellular DNA content, and clinical outcome in adenoid cystic carcinoma of the salivary glands. Otolaryngol Head Neck Surg 131 5 (2004) 646-650
122. Franzen G., Nordgard S., Boysen M., Lausen P.L., Halvorsen T.B., and Clausen O.P. DNA content in adenoid cystic carcinoma. Head Neck 17 1 (1995) 49-55